ArticleOncotarget2018
The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.Nature communications · 2024Trial
- Causal Interplay Between Inflammatory Cytokines and Lipid Metabolites in Serous Ovarian Carcinoma: Insights From a Genetic Association Study.Journal of clinical laboratory analysis · 2026Article
- Proteomic profiling of single extracellular vesicles as a promising new approach for the diagnosis and treatment modality of advanced ovarian cancer.NPJ precision oncology · 2026Article
- Long non-coding RNAs and VEGF in ovarian cancer: mechanisms and therapeutic potential.Journal of ovarian research · 2025Review
- Epigenetic modulation of VEGF-A/VEGFR2 pathway genes in OC/TME axis driving genetic upregulation and tumor plasticity.Scientific reports · 2025Article
- Detecting vascular normalization in epithelial ovarian cancer.Medical oncology (Northwood, London, England) · 2025Review
- Review
- Serum vascular endothelial growth factor associated with the progression of granulosa cell tumor: a report of two cases.Journal of ovarian research · 2023Article
- Article
- Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.International journal of molecular sciences · 2023Review
- Prognostic Role of Vascular Endothelial Growth Factor and Correlation with Oxidative Stress Markers in Locally Advanced and Metastatic Ovarian Cancer Patients.Diagnostics (Basel, Switzerland) · 2023Article
- Targeting the immune microenvironment for ovarian cancer therapy.Frontiers in immunology · 2023Review
- A single targeted gamma-ray irradiation induced an acute modulation of immune cells and related cytokines in EMT6 mouse-bearing tumour model.Cancer biomarkers : section A of Disease markers · 2023Article
- Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.Clinical and experimental immunology · 2022Review
- Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer.Biomolecules & therapeutics · 2021Article
- Heterotopic autotransplantation of ovarian tissue in a large animal model: Effects of cooling and VEGF.PloS one · 2020Article
- Antiangiogenesis Efficacy of Ethanol Extract fromEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Hypoxia-induced Maspin Expression Affects the Prognosis of Ovarian Clear Cell Carcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimAt present, numerous reports have shown that high/positive expression of tissue vascular endothelial growth factor (VEGF) may be associated with the prognosis of patients with ovarian cancer. However, their results still remained controversy. Thus, this meta-analysis was designed to analyze and assess the prognostic value of tissue VEGF expression in patients with ovarian cancer.
methodWe searched PubMed, Embase, Cochrane Library and Web of Science to October, 2017. Hazard Ratio (HR) with its 95% confidence intervals (CIs) was used to evaluate the association between high/positive expression of tissue VEGF and the prognosis of ovarian cancer patients. All statistical analyses were performed using standard statistical procedures provided in RevMan 5.2.
resultA total of 18 studies (including 1145 patients) were included for this meta-analysis. The positive/high expression of tissue VEGF had an obvious association with overall survival (OS) (HR 2.24, 95% CI 1.36-3.70;
conclusionThe present meta-analysis indicated that positive/high expression of tissue VEGF may have a close association with survival of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.